These are top 10 stocks traded on the Robinhood UK platform in July
On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Kura Oncology (NASDAQ:KURA) shares, which currently trade at $5.64, near their 52-week low and significantly below the highest analyst target of $40. According to InvestingPro data, analysts maintain a strong bullish consensus on the stock, with multiple upward earnings revisions for the upcoming period. The firm’s analyst highlighted the American Society of Clinical Oncology (ASCO) abstract regarding Kura’s ziftomenib, a MENIN inhibitor used in the treatment of NPM1m relapsed/refractory acute myeloid leukemia (R/R AML). The data presented showed a complete remission (CR) and complete remission with partial hematologic recovery (CRh) rate of 23%, which is consistent with the rates of competing drug revumenib and dispels concerns of a CR/CRh rate below 20%.
The analysis noted two significant distinctions between ziftomenib and revumenib. Firstly, ziftomenib demonstrated a substantially lower rate of grade 3 or higher QTc prolongation—a heart rhythm condition—compared to revumenib (2% versus 21%), which could represent a considerable safety benefit. Secondly, the duration of response (DoR) for ziftomenib was slightly shorter than that of revumenib (3.7 months versus 4.7 months). However, when considering the restricted mean duration of response, which provides a more accurate estimate in trials with high censoring and small sample sizes, ziftomenib’s DoR aligns closely with revumenib’s at approximately 4.3 months.
This endorsement from Cantor Fitzgerald comes after the review of the pivotal topline data from the clinical trial, which was deemed to meet expectations. The findings are important for Kura Oncology as they continue to develop and differentiate ziftomenib in the competitive landscape of AML treatments. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt on its balance sheet and a healthy current ratio of 8.07, indicating robust liquidity to fund its clinical programs.
Kura Oncology’s focus remains on advancing its pipeline of oncology treatments, with ziftomenib being a key asset. The company’s commitment to addressing the challenges of AML treatment is underscored by these recent findings, which will likely be a topic of interest at the upcoming ASCO meeting.
The stock market’s response to these developments will be observed as investors and stakeholders evaluate the potential impact of the new data on Kura Oncology’s market position and future prospects. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels. Subscribers can access 10+ additional ProTips and comprehensive financial metrics in the detailed Pro Research Report, providing deeper insights into KURA’s investment potential.
In other recent news, Kura Oncology Inc . reported its first-quarter 2025 earnings, highlighting a significant increase in revenue to $14.1 million from zero in the same quarter last year. This revenue boost was attributed to successful collaborations and advancements in its product pipeline. However, the company’s earnings per share (EPS) came in at -$0.66, slightly missing the forecast of -$0.62. Despite this, Kura Oncology’s cash position remains robust, expected to fund operations into 2027. The company is advancing its pipeline with new trials and product developments, including the potential commercial launch of Ziftomenib for acute myeloid leukemia (AML). Additionally, Kura Oncology has submitted a New Drug Application (NDA) for Ziftomenib, which has been granted breakthrough therapy designation for treatment of relapsed or refractory NPM1 mutant AML. Analysts from firms such as Cantor Fitzgerald and Leerink Partners have shown interest in Kura’s competitive positioning and upcoming data presentations, reflecting optimism about the company’s strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.